Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $402.49, representing a -1.13% change from its previous close.

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

Vertex Global Services partners with Arish Global Services to create 5,000 jobs in Delhi-NCR, focusing on business process ...

The FDA will decide later this month whether to approve a novel drug for acute pain that could offer a nonaddictive ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Artivion, Inc. AORT: This medical device and tissue ...

Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...

Like its competitors, Google continues to experiment with low- and no-code tools that harness agentic AI for business ...

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

The artificial intelligence (AI) boom has taken the stock market by storm. Wall Street is currently fixated on AI agents, which differ slightly from traditional AI copilots. Alphabet (NASDAQ: GOOGL) ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...